Tradestie Institutional Equity Comparison Engine

DMAC vs INBX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DMAC Overall Edge

DMAC Captures Institutional Edge (3โ€“0 Pillars ยท 4โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, DMAC trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus INBX at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro) against INBX sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
DMAC N/M vs INBX N/M Fwd P/E
Growth & Margin Winner DMAC
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs -100.0%
Momentum & Technical Winner DMAC
1Y +55.3% vs +3.6% ยท 52W Pos 55% vs 20%
Options & Structure Winner DMAC
SURGE (14th %ile IV) vs BREAKDOWN (8th %ile IV)
DMAC NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
1M Return +11.16%
1Y Return +55.26%
Forward P/E N/M
Unified AI Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
INBX NASDAQ
Inhibrx Biosciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$77.32
-7.18% 1D
Market Cap $1.3B
1M Return -13.93%
1Y Return +3.61%
Forward P/E N/M
Unified AI Score
49.8 / 100 HOLD
Tech 48.0 Fund 54.0 Flow 68.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DMAC +55.26% INBX +3.61% Spread: +51.65 pp (DMAC Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period DMAC Revenue INBX Revenue DMAC Op. Margin INBX Op. Margin Margin Edge
FY2018 $0M N/A -1352.2% N/A DMAC
FY2023 N/A $0M N/A -12178.9% INBX
FY2024 N/A $0M N/A -165724.0% INBX
FY2025 N/A $0M N/A -10386.5% INBX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DMAC (4) vs INBX (2)
Institutional Metric DMAC INBX Criterion Row Winner
Market Capitalization Scale $503.1M $1.3B Larger Scale INBX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -100.0% Higher Growth DMAC
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -114.6% -1773.6% Higher ROE DMAC
52-Week Range Position Momentum 55% ($5โ€“$11) 20% ($57โ€“$155) Stronger Trend DMAC
Beta / 30D Volatility Risk Regime 1.74ฮฒ ยท 98% Vol 2.53ฮฒ ยท 120% Vol Lower Realized Risk DMAC
Unified Institutional Score Composite Signal 46.3 / 100 (HOLD) 49.8 / 100 (HOLD) Higher Composite INBX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DMAC vs INBX Buy Guide
DMAC SURGE
8d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 14th %ile
IV Regime Compressed (<25th %ile)
Live DMAC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
INBX BREAKDOWN
134d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live INBX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DMAC nor INBX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.